Church of PeptidesSearch
Portrait of Liraglutide
New Disciples · approved 2010 / 2014

Liraglutide

The Daily Pilgrim

Denmark

Liraglutide is a GLP-1 receptor agonist used in separately labeled medicines for type 2 diabetes and chronic weight management. Its glucose and appetite effects come with product-specific eligibility, warnings, and limitations.

Evidence ladder: Approved human useApproved human use · product-specific labelsEducational record
ClassificationNew Disciples
Evidence summaryApproved human use · product-specific labels
OriginDenmark
Scientific record

What the evidence says

Established role or proposed benefit

  • Approved products support glycemic control or chronic weight management under separate labels.
  • Its engineered structure extends GLP-1 receptor activity.

Side effects, risks, and limits

  • Gastrointestinal effects are common.
  • Contraindications, interactions, and boxed-warning context must follow the exact product.
Doctide’s verdict

The Daily Pilgrim helped establish GLP-1 therapy’s clinical place. Doctide keeps that achievement tied to its actual labels and outcomes, rather than treating an older medicine as either obsolete or suitable for every purpose.

Documented history

Where the real story begins

Victoza received U.S. approval in January 2010. Saxenda followed in December 2014 for chronic weight management. In December 2024, FDA approved the first generic referencing Victoza, illustrating why approval history belongs to particular products as well as the underlying molecule. Historical source.

Denmark · approved 2010 / 2014
Book of the Canon · comic scripture

The laboratory legend

Liraglutide arrived once each day, carrying a slower version of an intestinal message. The pantry grew quieter, but the rulebook grew thicker.

This bold passage is invented comedy, not scientific or historical fact.
Editorial recordProfile editorial revision: October 4, 2026Prepared under the Church of Peptides evidence standardEditorial review: Church of PeptidesIndependent clinical review: none to dateContent evidence reviewed: September 12, 2026
Evidence ledger

Sources

Source links checked: October 4, 2026. This authoritative medication reference describes particular medicinal formulations and uses; it is not evidence for every preparation or off-label claim.

  1. MedlinePlus: medication-specific uses and precautions
  2. FDA Drugs@FDA database
  3. FDA clinical review: liraglutide approval history
  4. FDA first generic liraglutide approval, 2024

Fiction disclosure: The bold laboratory legend is invented. The historical and scientific sections are factual summaries; no invented connective events were added.

Educational entertainment only. Not medical advice, diagnosis, dosing guidance, or a recommendation to obtain or use a product.

The Book of Trials

Follow the research journey

Join Subject One for six short chapters, following documented research questions and today’s evidence.

Read the Liraglutide journey →